Alyeska Investment Group, L.P. Vaxcyte, Inc. Transaction History
Alyeska Investment Group, L.P.
- $25.4 Billion
- Q2 2025
A detailed history of Alyeska Investment Group, L.P. transactions in Vaxcyte, Inc. stock. As of the latest transaction made, Alyeska Investment Group, L.P. holds 244,775 shares of PCVX stock, worth $10.5 Million. This represents 0.03% of its overall portfolio holdings.
Number of Shares
244,775
Previous 164,640
48.67%
Holding current value
$10.5 Million
Previous $6.22 Million
28.01%
% of portfolio
0.03%
Previous 0.03%
Shares
7 transactions
Others Institutions Holding PCVX
# of Institutions
322Shares Held
139MCall Options Held
229KPut Options Held
160K-
Janus Henderson Group PLC London, X014.7MShares$630 Million0.25% of portfolio
-
Vanguard Group Inc Valley Forge, PA12MShares$515 Million0.01% of portfolio
-
Ra Capital Management, L.P. Boston, MA12MShares$513 Million8.5% of portfolio
-
Black Rock Inc. New York, NY9.94MShares$426 Million0.02% of portfolio
-
T. Rowe Price Investment Management, Inc. Baltimore, MD6MShares$257 Million0.12% of portfolio
About Vaxcyte, Inc.
- Ticker PCVX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 59,315,100
- Market Cap $2.54B
- Description
- Vaxcyte, Inc., a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine that is in Phase 1/2 clinical trials to treat invasive pneumococcal disease and pneumonia. The company a...